KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLong-Term Debt IssuancesLong-Term Debt RepaymentsR&D In ProcessShares RepurchasedShort-Term Debt issuances
Ratios

Eli Lilly (LLY) Short-Term Debt issuances (2016 - 2025)

Historic Short-Term Debt issuances for Eli Lilly (LLY) over the last 16 years, with Q4 2025 value amounting to -$400000.0.

  • Eli Lilly's Short-Term Debt issuances fell 10001.31% to -$400000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$4.3 billion, marking a year-over-year decrease of 13423.33%. This contributed to the annual value of -$4.3 billion for FY2025, which is 13423.33% down from last year.
  • Per Eli Lilly's latest filing, its Short-Term Debt issuances stood at -$400000.0 for Q4 2025, which was down 10001.31% from -$4.1 billion recorded in Q3 2025.
  • In the past 5 years, Eli Lilly's Short-Term Debt issuances ranged from a high of $4.6 billion in Q4 2023 and a low of -$5.2 billion during Q1 2024
  • For the 5-year period, Eli Lilly's Short-Term Debt issuances averaged around -$11.8 million, with its median value being -$2.5 million (2021).
  • Its Short-Term Debt issuances has fluctuated over the past 5 years, first crashed by 963200.0% in 2022, then soared by 198820.39% in 2023.
  • Eli Lilly's Short-Term Debt issuances (Quarter) stood at -$2.5 million in 2021, then tumbled by 9632.0% to -$243.3 million in 2022, then skyrocketed by 1988.2% to $4.6 billion in 2023, then crashed by 33.78% to $3.0 billion in 2024, then tumbled by 100.01% to -$400000.0 in 2025.
  • Its Short-Term Debt issuances stands at -$400000.0 for Q4 2025, versus -$4.1 billion for Q3 2025 and $1.6 billion for Q2 2025.